Roche announced today the completion of its acquisition of LumiraDx’s Point-of-Care technology, following the necessary antitrust and regulatory approvals. The acquisition will see Roche integrate LumiraDx’s multi-assay point-of-care platform, along with its R&D, operational, and commercial sites, into Roche’s global operations.
This acquisition enhances Roche’s diagnostics portfolio with a versatile platform capable of conducting a broad spectrum of immunoassay and clinical chemistry tests, and has potential to include molecular testing in the future. The integration will enable Roche to expand its reach in decentralized patient care, providing timely and actionable diagnostic results worldwide.
Access to diagnostic testing is crucial for global healthcare delivery. We believe the LumiraDx platform will help us increase the availability of testing, particularly in primary care settings and low-to-middle-income countries,” said Matt Sause, CEO of Roche Diagnostics.
Veronique Ameye, CEO of LumiraDx, expressed enthusiasm for the acquisition: “Joining the Roche network allows us to fully realize the potential of our Point-of-Care technology, increasing patient access to community-based healthcare globally. We look forward to collaborating to enhance patient outcomes.”
Roche first announced the agreement to acquire LumiraDx’s Point-of-Care technology in late 2023.
Continued Partnership with the Bill & Melinda Gates Foundation
Roche will continue its partnership with the Bill & Melinda Gates Foundation to advance the platform’s molecular diagnostic capabilities, including the development of a rapid molecular tuberculosis test. This test aims to address the global challenge of undiagnosed tuberculosis, which affects over 4 million people worldwide. The goal is to provide a cost-effective diagnostic solution suitable for remote settings, aiding in better detection and treatment to meet global health targets.
About Roche
Founded in 1896 in Basel, Switzerland, Roche has grown into the world’s largest biotechnology company and a leader in in-vitro diagnostics. The company focuses on scientific excellence to develop medicines and diagnostics that improve and save lives. Roche is a pioneer in personalized healthcare and aims to revolutionize healthcare delivery through its combined strengths in diagnostics, pharmaceuticals, and data insights.
Roche has been recognized as one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for fifteen consecutive years, reflecting its commitment to improving healthcare access worldwide.
Genentech, a wholly-owned member of the Roche Group, operates in the United States, and Roche is the majority shareholder in Japan’s Chugai Pharmaceutical.
